Neobiomics is pleased to invite you to the upcoming NeoMega36® Webinar, where leading experts in neonatology will share the latest scientific evidence and clinical experiences on ARA and DHA supplementation in extremely preterm infants.
Topic: ARA & DHA Supplementation in Extremely Preterm Infants- Clinical Experiences of NeoMega36® from 2 Europen NICUs
What to expect:
Dr. Norbert Teig will provide an overview of nearly two years of clinical experience using ARA and DHA supplementation in extremely preterm infants in his German NICU. He will discuss the rationale for implementing this approach, share observed outcomes, and highlight key learnings and practical insights from everyday clinical practice.
Dr. Jiří Dušek will present one year of clinical experience with ARA and DHA supplementation in his Czech NICU. He will describe the implementation process, review clinical outcomes, and share the practical insights and lessons learned from incorporating this intervention into routine neonatal care.
Introduction to NeoMega36® – supporting the normal vision development in extremely preterm infants, an innovative solution containing arachidonic acid (ARA) and docosahexaenoic acid (DHA).
Agenda:
15:30: Welcome and Introduction of NeoMega36®– Dr. Stefan Johansson
15:40: German Clinical Experience: Building Experience with ARA and DHA: Nearly Two Years Supporting Visual Development in Extremely Preterm Infants - Dr. Norbert Teig, Consultant Neonatologist, Department of Pediatrics and Adolescent Medicine, Catholic Hospital Bochum, Germany
15:50: Insights from the Czech Republic: Implementing ARA and DHA Supplementation: One Year of Clinical Experience in a Czech NICU- Dr. Jiří Dušek, Head of the Department of Neonatology, České Budějovice Hospital, Czech Republic